Insight Molecular Diagnostics Inc. Common Stock IMDX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 51.3%-3.0pp | 57%+12.9pp | 55.2%— | 55.5%— | 54.3%— | |
| Operating margin | -2,500.7%-977pp | -1,260.8%+1,984pp | -1,392.9%+4,756pp | -1,498.3%+2,079pp | -1,524.1%+1,389pp | |
| Net margin | -2,454.6%-940pp | -1,238.5%+1,987pp | -1,380.7%+4,704pp | -1,489.7%+2,043pp | -1,514.6%+1,376pp | |
| EBITDA margin | -2,380.8%-899pp | -1,206.8%+1,960pp | -1,343.7%+4,630pp | -1,453.6%+1,994pp | -1,481.3%+1,326pp | |
| Free cash flow margin | -1,409.7%-798pp | -625.6%+502pp | -543.2%+2,324pp | -563.2%— | -611.4%— | |
| Returns | ||||||
| Return on assets | -94.9%-6.3pp | -165.1%-54.8pp | -106.5%-49.6pp | -101.3%-56.7pp | -88.6%-36.7pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×0.0× | |
| Inventory turnover | 2.3×— | 4.1×— | 5.6×— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 2.5×-1.2× | 1.3×-0.3× | 2.8×+2.3× | 4×+2.7× | 3.7×+3.0× | |
| Quick ratio | 2.5×-1.2× | 1.2×-0.3× | 2.7×+2.2× | 3.9×+2.5× | 3.7×+2.9× | |
| Cash ratio | 2.3×-0.9× | 1×-0.2× | 2.4×+2.1× | 3.7×+2.4× | 3.2×+2.5× | |
| Leverage | ||||||
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×— | |
| Per Share | ||||||
| Book value per share | -$0.31-178% | -$1.03-9.9% | -$0.29-141% | $0.03-98.1% | $0.40-71.6% | |
| Valuation | ||||||
| Market capitalization | $185.35M+92.3% | $214.98M— | $95.02M— | $98.67M— | —— | |
| Enterprise value | $160.03M+113% | $206.72M— | $79.27M— | $77.58M— | —— | |
| Price / sales | 95.1×+72.5× | 53×— | 21.6×— | 23.2×— | —— | |
| EV / sales | 82.1×+64.4× | 51×— | 18×— | 18.2×— | —— | |
| Free cash flow yield | -14.8%+10.1pp | -11.8%— | -25.2%— | -24.3%— | —— | |
| Earnings yield | -25.8%+40.0pp | -23.4%— | -64%— | -64.3%— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) runs a 51.3% gross margin and a -2500.7% operating margin, with a -2454.6% net margin.
- Where do Insight Molecular Diagnostics Inc. Common Stock's ratios come from?
- Every ratio is computed from Insight Molecular Diagnostics Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
